146 related articles for article (PubMed ID: 9212919)
1. In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines.
Agrawal S; Tan W; Cai Q; Xie X; Zhang R
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):245-9. PubMed ID: 9212919
[No Abstract] [Full Text] [Related]
2. Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.
Geary RS; Watanabe TA; Truong L; Freier S; Lesnik EA; Sioufi NB; Sasmor H; Manoharan M; Levin AA
J Pharmacol Exp Ther; 2001 Mar; 296(3):890-7. PubMed ID: 11181921
[TBL] [Abstract][Full Text] [Related]
3. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration.
Agrawal S; Zhang X; Lu Z; Zhao H; Tamburin JM; Yan J; Cai H; Diasio RB; Habus I; Jiang Z
Biochem Pharmacol; 1995 Aug; 50(4):571-6. PubMed ID: 7646565
[TBL] [Abstract][Full Text] [Related]
4. In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats.
Zhang R; Lu Z; Zhang X; Zhao H; Diasio RB; Liu T; Jiang Z; Agrawal S
Clin Chem; 1995 Jun; 41(6 Pt 1):836-43. PubMed ID: 7768001
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion.
Grindel JM; Musick TJ; Jiang Z; Roskey A; Agrawal S
Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):43-52. PubMed ID: 9512095
[TBL] [Abstract][Full Text] [Related]
6. Characterization and quantification of Bcl-2 antisense G3139 and metabolites in plasma and urine by ion-pair reversed phase HPLC coupled with electrospray ion-trap mass spectrometry.
Dai G; Wei X; Liu Z; Liu S; Marcucci G; Chan KK
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Oct; 825(2):201-13. PubMed ID: 16111926
[TBL] [Abstract][Full Text] [Related]
7. Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey.
Yu RZ; Geary RS; Leeds JM; Watanabe T; Moore M; Fitchett J; Matson J; Burckin T; Templin MV; Levin AA
J Pharm Sci; 2001 Feb; 90(2):182-93. PubMed ID: 11169535
[TBL] [Abstract][Full Text] [Related]
8. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides.
Levin AA
Biochim Biophys Acta; 1999 Dec; 1489(1):69-84. PubMed ID: 10806998
[No Abstract] [Full Text] [Related]
9. Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2'-O-methyl phosphodiester oligonucleotides in normal rats.
Lendvai G; Velikyan I; Bergström M; Estrada S; Laryea D; Välilä M; Salomäki S; Långström B; Roivainen A
Eur J Pharm Sci; 2005 Sep; 26(1):26-38. PubMed ID: 15941654
[TBL] [Abstract][Full Text] [Related]
10. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides.
Agrawal S
Biochim Biophys Acta; 1999 Dec; 1489(1):53-68. PubMed ID: 10806997
[TBL] [Abstract][Full Text] [Related]
11. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats.
Geary RS; Khatsenko O; Bunker K; Crooke R; Moore M; Burckin T; Truong L; Sasmor H; Levin AA
J Pharmacol Exp Ther; 2001 Mar; 296(3):898-904. PubMed ID: 11181922
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1.
Zhang R; Diasio RB; Lu Z; Liu T; Jiang Z; Galbraith WM; Agrawal S
Biochem Pharmacol; 1995 Mar; 49(7):929-39. PubMed ID: 7741765
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects.
Zhang R; Yan J; Shahinian HK; Amin G; Lu Z; Liu T; Saag MS; Jiang Z; Temsamani J; Martin RR
Clin Pharmacol Ther; 1995 Jul; 58(1):44-53. PubMed ID: 7628182
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of oligonucleotides.
Agrawal S; Zhang R
Ciba Found Symp; 1997; 209():60-75; discussion 75-8. PubMed ID: 9383569
[TBL] [Abstract][Full Text] [Related]
15. In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats.
Zhang R; Lu Z; Zhao H; Zhang X; Diasio RB; Habus I; Jiang Z; Iyer RP; Yu D; Agrawal S
Biochem Pharmacol; 1995 Aug; 50(4):545-56. PubMed ID: 7646561
[TBL] [Abstract][Full Text] [Related]
16. Effect of aspirin on protein binding and tissue disposition of oligonucleotide phosphorothioate in rats.
Agrawal S; Zhang X; Cai Q; Kandimalla ER; Manning A; Jiang Z; Marcel T; Zhang R
J Drug Target; 1998; 5(4):303-12. PubMed ID: 9713979
[TBL] [Abstract][Full Text] [Related]
17. Rapid plasma clearance and metabolism in vivo of a phosphorothioate oligodeoxynucleotide with a single, internal phosphodiester bond.
Boado RJ; Kang YS; Wu D; Pardridge WM
Drug Metab Dispos; 1995 Nov; 23(11):1297-300. PubMed ID: 8591734
[No Abstract] [Full Text] [Related]
18. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.
Saijo Y; Perlaky L; Wang H; Busch H
Oncol Res; 1994; 6(6):243-9. PubMed ID: 7865900
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
[TBL] [Abstract][Full Text] [Related]
20. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide.
Temsamani J; Roskey A; Chaix C; Agrawal S
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):159-65. PubMed ID: 9212906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
